Plasma Endothelin‐1 in patients with atrial septal defect – the novel diagnostic indicator (RCD code: IV-2B.1)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 3
Abstract
Background: The study aimed to assess the level of plasma Endothelin-1 (ET-1) in patients before and after transcatheter closure of atrial septal defect (ASD) and to evaluate the usefulness of measuring ET-1 levels for the diagnosis and selection of candidates for ASD closure.Methods: 21 patients (11 F, 10 M), mean age 40.2 ± 11.9 years with pulmonary artery hypertension were enrolled for an attempt at ASD closure. A group of 19 healthy volunteers, (12 F, 7 M) mean age 39.2 ± 9.15 served as controls. All ASD patients underwent: clinical and echocardiographic study and cardiopulmonary exercise test. ET-1 levels were measured before and after closure. Whole blood was collected from femoral artery and vein and from pulmonary artery during cardiac catheterization.Results: ET-1 levels at peripheral artery and vein in ASD patients were significantly higher than in the volunteers (p<0.0001). The ASD subjects with highest ET-1 level presented the larger area of right ventricle and right atrium and higher pulmonary artery systolic pressure(p<0.05). The ASD subjects with lower ET-1 level demonstrated longer time of exercise and higher peak oxygen consumption (p<0.05). There was a decrease of ET-1 at peripheral artery (5.549 ± 5.32 vs. 1.92 ± 7.2; p<0.001) and at peripheral vein (4.012 ± 2.342 vs. 2.15 ± 1.15; p<0.001) within 48 hours after ASD closure, as compared to the baseline data. After 6 and 12 months farther drop in ET-1 level was observed.Conclusions: 1. The level of ET-1 in patients with ASD and pulmonary artery hypertension is elevated in compare to healthy subject. 2. The significant reduction of ET-1 level is observed after percutaneous closure of ASD.3. Elevated level of ET-1 in patients with ASD is associated with right heart enlargement. 4. Measurements of ET-1 may be a supplemental diagnostic tool and may be helpful in establishing indications for defect closure.
Authors and Affiliations
Monika Komar, Jakub Podolec, Urszula Gancarczyk, Wojciech Płazak, Bartosz Sobień, Lidia Tomkiewicz‐Pająk, Piotr Wilkołek, Tadeusz Przewłocki
Keywords
Related Articles
- EP ID EP245467
- DOI 10.20418/jrcd.vol2no3.184
- Views 96
- Downloads 0
Update on myocarditis – review (RCD code: III-6A.1)
Myocardits is an inflammatory disease of the myocardium diagnosed by established histological and immunohistochemical criteria. The true incidence of myocarditis is unknown. There are numerous potential etiologic factors...
Myxoma of the heart (RCD code: VI-1A.1)
Myxomas are the most common primary benign intracardiac tumors. Typically they locate in the left atrium (LA) or right atrium (RA) and are composed of cells, that originate from multipotent mesenchyme. The clinical manif...
Severe aortic regurgitation and pulmonary hypertension in an 18‑year‑old patient after balloon aortic valvuloplasty (RCD code: IV‑5.A2)
Aortic stenosis is the most common form of congenital left ventricle outflow tract obstruction. It may be a life threatening ductal-dependent condition in newborns and necessitating urgent percutaneous balloon aortic val...
Giant cell myocarditis: challenge of mechanical circulatory support (RCD code: III-1B.1.o)
We report the case of a young adult male who presented with acute fulminant myocarditis, deteriorated rapidly despite intra‑aortic balloon pump and inotropic support, and received a HeartMate II continuous flow left vent...
Highlights from the Polish Pulmonary Hypertension Patients and their Friends Meeting in Krakow
Annual Meeting of the Pulmonary Hypertension Patients and their Friends organized by Pulmonary Hypertension Association (PHA) of Poland was held on June 11, 2016 at the Department of Cardiac and Vascular Diseases of the...